Skip to main content
Premium Trial:

Request an Annual Quote

Cronus Distributing PamGene Technology in UK, Ireland

NEW YORK (GenomeWeb News) – Cronus Technologies has inked a distribution deal with PamGene International covering the UK and Ireland.

The deal, the terms of which were not disclosed, calls for UK-based Cronus to sell and market the PamStation 12 and PamChip microarrays. The PamStation 12 is a fully automated instrument for processing PamChip microarrays that provides real-time measurement of peptide phosphorylation by protein kinases in any sample type.

According to Cronus, the technology allows researchers to analyze kinase activity rather than presence "which is crucial to elucidate new signal transduction pathways, develop novel drug targets, and test kinase inhibitors." Additionally, it can also be used to develop algorithms for patient prognosis and prediction of response to treatments.

PamGene Managing Director Tim Kievets said that in addition to growing the network of PamGene users, the deal will allow his firm to develop more applications for the technology.

Based in The Netherlands, PamGene develops technology and applications for measuring cellular kinase activity and nuclear receptor activity.

Cronus distributes technologies for the cell and molecular biology market. In February, it and Axela signed a distribution deal covering Axela's instruments in the UK and Ireland.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.